| | | | |
| CLDX | 4.11 | Phase 2b | 05/23/2012 | Phase 2b interim, topline data of CDX-011 for Metastatic breast due to be released May 23, 2012 |
| DND | 1.30 | PDUFA | 05/29/2012 | PDUFA date Mat 29, 2012 for CIP-ISOTRETINOIN, a formulation of the acne medication isotretinoin, |
| CHTP | 1.99 | FDA Meeting | 05/31/2012 | FDA meeting scheduled 2Q 2012 following Northera Complete Response Letter |
| ARIA | 15.98 | PDUFA | 06/05/2012 | PDUFA June 5 2012 of ridaforolimus for metastatic soft-tissue or bone sarcomas |
| XNPT | 5.83 | PDUFA | 06/09/2012 | PDUFA 6/9/12 for sNDA of Horizant for post-herpetic neuralgia (PHN) |
| ONXX | 41.82 | Advisory Committee | 06/20/2012 | Oncologic Drugs Advisory Committee (ODAC) to meet June 20 to review Captisol-enabled Carfilzomib, for the treatment for multiple myeloma, partnered with LGND. |
| LGND | 11.71 | Advisory Committee | 06/20/2012 | Oncologic Drugs Advisory Committee (ODAC) to meet June 20 to review Captisol-enabled Carfilzomib, for the treatment for multiple myeloma, partnered with ONXX. |
| RGEN | 4.48 | PDUFA | 06/21/2012 | PDUFA June 21 2012 of RG1068 - SecreFlo for Pancreatic imaging under priority review - COMPANY EXPECTS CRL |
| ARNA | 5.52 | PDUFA | 06/27/2012 | PDUFA date June 27 2012 for lorcaserin in patients with obesity |
| ALKS | 16.42 | Phase 2 | 06/30/2012 | Phase 2b data of Opioid-induced constipation mid-2012 |
| ALNY | 9.91 | Phase 2 | 06/30/2012 | Phase 2b data for RSV (respiratory syncytial virus) infected adult lung transplant patients due mid 2012) |
| ALTH | 1.79 | Phase 1/2 | 06/30/2012 | Phase 1/2 FOLOTYN data 2nd line Non-Hodgkin Lymphoma combination Pralatrexate + Gemcitabine 1H 2012 |
| ANTH | 1.95 | Phase 2b | 06/30/2012 | Phase 2b topline data of A-623 Blisibimod for lupus due 2Q 2012 |
| APPA | 0.49 | NDA filing | 06/30/2012 | NDA filing of APF530 due mid 2012 for patients with chemotherapy-induced nausea and vomiting |
| APPY | 0.56 | Phase 3 | 06/30/2012 | Pivotal trial initiation of AppyScore for diagnosis of appendicitis expected mid 2012 |
| ARIA | 15.98 | Phase 2 | 06/30/2012 | Phase 2 trial of AP26113 for ALK-positive and EGFR-positive lung cancer to be initiated mid 2012 |
| ARRY | 3.49 | Phase 2 | 06/30/2012 | Further Phase 2 data of Selumetinib (AZD6244) plus docetaxel for NSCLC due 2Q 2012 |
| ASTM | 2.01 | Phase 2 | 06/30/2012 | Initiate Phase 2b ixmyelocel-T for DCM in 1H 2012 |
| CHTP | 1.99 | Phase 2 | 06/30/2012 | Phase 2 topline data for Rheumatoid Arthritis due 2Q |
| CLDX | 4.11 | Phase 2b | 06/10/2012 | Phase 2b data of CDX-011 Metastatic breast due at ASCO early June 2012 |
| CRIS | 4.47 | Phase 1/2 | 06/30/2012 | Phase 1/2 initiation of Debio 0932 for lung cancer 2Q 2012 |
| CYTK | 0.90 | Phase 2b | 06/30/2012 | Decision regarding progression to the second cohort of the ATOMIC-AHF trial in 2Q 2012 following a review of data from the first cohort |
| DRRX | 0.76 | | 06/30/2012 | Pfizer to conduct two bioavailability studies in 2Q 2012 and then meet with the FDA during 3Q to discuss next steps for REMOXY |
| ECYT | 4.52 | Phase 2 | 06/30/2012 | Phase 2 initiation of EC145 for NSCLC 2Q 2012 |
| EXEL | 4.61 | Phase 3 | 06/30/2012 | Phase 3 2Q 2012 initiation of Castration-Resistant Prostate Cancer - 2nd Phase 3 COMET-1, focused on overall survival |
| EXEL | 4.61 | NDA Filing | 06/30/2012 | Rolling NDA of XL184 cabozantinib for Medullary thyroid cancer to be completed 1H 2012 |
| FOLD | 4.67 | Phase 2 | 06/30/2012 | Interim Phase 2 data of Migalastat co-administered with enzyme replacement therapy (ERT) for Fabry disease (Study 013) due 3Q 2012 with final results due at Fall 2012 scientific conference |
| FOLD | 4.67 | Phase 2 | 06/30/2012 | Phase 2 preliminary data of AT2220 co-administered with the ERT alglucosidase alfa in patients with Pompe Disease due 2Q 2012 |
| HALO | 7.90 | Phase 3 | 06/30/2012 | Complete Phase 2 study with Viropharma for SC Cinryze - 1H 2012 |
| HGSI | 13.99 | Phase 3 | 06/30/2012 | Initial Phase 3 data of Albiglutide for Type 2 diabetes due mid 2012 |
| INSM | 2.87 | Phase 2 | 06/30/2012 | Phase 2 initiation of ARIKACE in patients with non-tuberculous mycobacteria (NTM) lung disease mid 2012 |
| ISTA | 9.07 | NDA filing | 06/30/2012 | NDA filing of PROLENSA for Postoperative inflammation and reduction of ocular pain post-cataract extraction due 1H 2012 |
| ISTA | 9.07 | Phase 2 | 06/30/2012 | Phase 2 data of BEPOSONE for Seasonal allergic rhinitis due 1H 2012 |
| LGND | 11.71 | Phase 3 | 06/30/2012 | Initiate pivotal trial of Captisol-Enabled Melphalan for multiple myeloma duirng 2012 |
| LGND | 12.16 | NDA filing | 06/30/2012 | NDA filing of Aprela for Menopausal symptoms due "soon" as of May 2 2012. End of 2Q estimate only |
| LXRX | 1.51 | Phase 2 | 06/30/2012 | Phase 2b data of LX4211 for diabetes due mid 2012 |
| LXRX | 1.51 | Phase 2 | 06/30/2012 | Phase 2 data of LX2931 in rheumatoid arthritis patients due 2Q 2012 |
| MAPP | 11.54 | FDA Meeting | 06/30/2012 | FDA meeting scheduled 2Q 2012 following LEVADEX Complete Response Letter |
| MDCO | 20.88 | Phase 2b | 06/30/2012 | Phase 2b initiation of MDCO-2010 for Reduction of blood loss during surgery 2Q 2012 |
| MDCO | 20.88 | Phase 3 | 06/30/2012 | Phase 3 enrolment completion of Oritavancin for ABSSSI 2Q 2012 |
| MDVN | 83.15 | Phase 3 | 06/30/2012 | Phase 3 Dimebon CONCERT Huntington disease trial data due 1H |
| MDVN | 83.15 | Phase 3 | 06/30/2012 | NDA filing of enzalutamide in post-chemotherapy prostate cancer patients due to be filed 2Q 2012 |
| MNOV | 3.15 | Phase 2 | 06/30/2012 | Phase 2 preliminary data of MN-221-CL-007 for acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations due 2Q 2012 |
| NBIX | 6.55 | Phase 3 | 06/30/2012 | Initiate Phase 3 Elagolix for endometriosis 2Q 2012 |
| NBIX | 6.55 | Phase 2 | 06/30/2012 | Initiate Phase 2b trial of NBI-98854 in tardive dyskinesia patients mid 2012 |
| NLNK | 11.21 | Phase 2 | 06/30/2012 | Phase 2b/3 initiation of NSCLC 1H 2012 |
| NLNK | 11.21 | Phase 2 | 06/30/2012 | Phase 2 data of HyperAcute Melanoma due 1H 2012 |
| OREX | 3.44 | | 06/30/2012 | Expect to initiate cardiovascular outcomes trial late 2Q 2012 for Contrave for obesity |
| PATH | 3.03 | NDA filing | 06/30/2012 | Resubmit NDA for migraine patch 1H 2012 |
| PCYC | 28.60 | Phase 2 | 06/30/2012 | Phase 2 PCI-32765 for Diffuse Large B-cell Lymphoma (DLBCL), complete enrolment 1H (1106) |
| PCYC | 28.60 | Phase 2 | 06/30/2012 | Phase 2 PCI-27483 for pancreatic cancer interim data due 1H 2012 |
| PCYC | 28.60 | Phase 2 | 06/30/2012 | Phase 2 complete enrolment of PCI-32765 for relapsed or refractory MCL 1H 2012 |
| PCYC | 28.60 | Phase 2 | 06/30/2012 | Phase 2 data (initial) due mid 2012 of PCI-32765 in combination with ofatumumab (PCYC-1109) for CLL/SLL |
| PCYC | 28.60 | Phase 2 | 06/30/2012 | Phase 2 data (initial) due mid 2012 of PCI-32765 (PCYC-1102) CLL/SLL |
| PGNX | 7.52 | NDA filing | 06/30/2012 | NDA filing of Oral Methylnaltrexone for Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation due mid 2012 |
| PPHM | 0.44 | Phase 2 | 06/30/2012 | Phase 2 Data Bavituximab for Refractory NSCLC to be unblinded 1H 2012 |
| PPHM | 0.44 | Phase 2 | 06/30/2012 | Phase 2 interim Data Bavituximab for pancreatic cancer due sometime during 2012 |
| RIGL | 7.55 | Phase 2 | 06/30/2012 | Phase 2 initiation of R333 for Discoid Lupus Erythematosus during summer of 2012 |
| SCMP | 8.00 | sNDA filing | 06/30/2012 | sNDA filing for Opioid-induced bowel dysfunction expected mid-2012 |
| SNTA | 3.80 | Phase 2b | 06/30/2012 | Phase 2b interim data of Ganetespib for NSCLC due 2Q 2012 |
| THRX | 20.33 | NDA filing | 06/30/2012 | NDA filing of Relovair for chronic obstructive pulmonary disease (copd) due mid 2012 |
| THRX | 20.33 | Phase 2b | 06/30/2012 | Phase 2b data of TD−1211 for Opioid-induced constipation (OIC) due mid-2012 |
| TZYM | 3.00 | Phase 3 | 06/30/2012 | Phase 3 topline data of Ulimorelin ULISES 008 trial due by end of June 2012 |
| VTUS | 10.50 | Phase 3 | 06/30/2012 | First of two Phase 3 trials of VEN 309 (iferanserin) for Symptomatic hemorrhoids. Data due late June early July 2012. June 30 midpoint estimate only |
| XOMA | 2.37 | Phase 3 | 06/30/2012 | Phase 3 initiation of Behcet's uveitis 2Q 2012 |
| YMI | 1.97 | Phase 1/2 | 06/30/2012 | Phase 1/2 Prelim data of CYT997 in glioma expected 1H 2012 |
| YMI | 1.97 | Phase 3 | 09/30/2012 | Phase 3 initiation of CYT387 for Myelofibrosis planned 3Q 2012 |
| VVUS | 22.92 | PDUFA | 07/17/2012 | PDUFA 7/17/12 of Qnexa for obesity. 3 month extension due to REMS submission |
| HZNP | 3.80 | PDUFA | 07/26/2012 | PDUFA 7/26/12 of LODOTRA for rheumatoid arthritis |
| AMRN | 10.07 | PDUFA | 07/26/2012 | PDUFA 7/26/12 of AMR101 for very high triglyceride levels |
| ONXX | 41.82 | PDUFA | 07/27/2012 | PDUFA date of July 27, 2012 for Onyx Pharmaceuticals,for Captisol-enabled Carfilzomib, for the treatment for multiple myeloma, partnered with LGND |
| LGND | 11.71 | PDUFA | 07/27/2012 | PDUFA date of July 27, 2012 for Onyx Pharmaceuticals,for Captisol-enabled Carfilzomib, for the treatment for multiple myeloma, partnered with LGND |
| PGNX | 7.52 | PDUFA | 07/27/2012 | PDUFA 7/27/12 for subcutaneous RELISTOR for chronic pain - extended by 3 months |
| SLXP | 49.03 | PDUFA | 07/27/2012 | PDUFA 7/27/12 for subcutaneous RELISTOR for chronic pain - extended by 3 months |
| ZIOP | 4.44 | Phase 3 | 07/31/2012 | Phase 3 initiation of palifosfamide for small cell lung SCLC by early 3Q 2012 |
| TLON | 0.75 | PDUFA | 08/12/2012 | PDUFA 8/12/12 for Marqibo for 2nd line adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) - extended 3mths from original PDUFA date |
| GILD | 49.94 | PDUFA | 08/27/2012 | PDUFA August 27 2012 for Quad, a complete single-tablet HIV regimen containing elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. |
| ARRY | 3.58 | Phase 2 | 08/31/2012 | Phase 2 topline data of ARRY 797 for pain due summer 2012 |
| DCTH | 2.60 | NDA filing | 08/31/2012 | NDA filing for CHEMOSAT system due August 2012 |
| DRRX | 0.76 | NDA meeting | 08/31/2012 | Pre-NDA meeting for POSIDUR summer 2012 |
| RIGL | 8.07 | Phase 2 | 08/31/2012 | Phase 2 initiation of R343 for asthma during late summer of 2012 |
| SLXP | 49.40 | PDUFA | 09/05/2012 | PDUFA Sept 5 2012 crofelemer for diarrhea in patients with HIV/AIDS on anti-retroviral therapy (ART). PDUFA extended by 3 months |
| IRWD | 11.27 | PDUFA | 09/09/2012 | PDUFA date extended by 3 mths, likely early Sept 2012 for irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC) - exact date TBC |
| NAVB | 2.94 | PDUFA | 09/10/2012 | PDUFA 9/10/12 for Lymphoseek - Lymphatic-tissue tracing agent. 3-month extension from original date |
| ARIA | 15.98 | NDA filing | 09/30/2012 | NDA filing of Oral ponatinib for chronic myeloid leukemia, acute lymphoblastic leukemia due 3Q 2012 |
| ARIA | 15.98 | Phase 3 | 09/30/2012 | Phase 3 initiation of ponatinib in newly diagnosed chronic myeloid leukemia, acute lymphoblastic leukemia 3Q 2012 |
| AVEO | 11.28 | NDA filing | 09/30/2012 | NDA for tivozanib in patients with advanced renal cell carcinoma due to be filed 3Q 2012 |
| BCRX | 3.30 | Phase 3 | 09/30/2012 | Phase 3 Peramivir - Interim analysis due following end of Southern Hemishphere flu season |
| BCRX | 3.30 | Phase 2 | 09/30/2012 | Complete enrolment of BCX4208 for Moderate renal impairment 3Q 2012 |
| BDSI | 2.20 | Pivotal | 09/30/2012 | Data from pivotal pharmacokinetic study of BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence due late 3Q 2012 |
| BDSI | 2.20 | Pivotal | 09/30/2012 | Initiate two Phase 3 trials of BEMA Buprenorphine for chronic pain during 3Q 2012 |
| BIOD | 0.65 | Phase 2 | 09/30/2012 | Phase 2 BIOD-123 trial in patients with Type 1 Diabetes due to be initiated 3Q 2012 |
| FOLD | 4.67 | Phase 3 | 09/30/2012 | Phase 3 data (Study 011) of migalastat HCl for Fabry disease due 3Q 2012. |
| FURX | 15.76 | Phase 3 | 09/30/2012 | Phase 3 initiation of MuDelta for diarrhea-predominant irritable bowel syndrome 3Q 2012 |
| GTXI | 3.41 | Phase 3 | 09/30/2012 | Intends to initiate Phase 2 trial on lower dose of GTx-758 Capesaris in patients with prostate cancer, during 3Q 2012 |
| NBY | 1.37 | Phase 2 | 09/30/2012 | Topline Phase 2 data NVC422 for urinary infection due later in 2012 - 3Q estimate only |
| NBY | 1.03 | Phase 2 | 09/30/2012 | Ph2b initiation of NVC422 for Impetigo skin infection later in 2012 - 3Q estimate only |
| NGSX | 0.33 | FDA meeting | 09/30/2012 | End of Phase 2 meeting for NGX-1998 for Neuropathic pain planned for 3Q 2012 with possible Phase 3 initiation late 2012 |
| NPSP | 7.13 | PDUFA | 09/30/2012 | PDUFA date of September 30, 2012 for Gattex for the treatment of adult short bowel syndrome or SBS. |
| NVAX | 1.16 | Phase 2 | 09/30/2012 | Phase 2 topline data for seasonal flu vaccine due 3Q 2012 |
| PTN | 0.60 | Phase 2 | 09/30/2012 | Phase 2b data of bremelanotide for female sexual dysfunction (FSD) due 3Q 2012 |
| RNN | 0.40 | Phase 2 | 09/30/2012 | Phase 2 data of Archexin for pancreatic cancer due 3Q 2012 |
| RPRX | 7.40 | Phase 3 | 09/30/2012 | Hopes to initiate a Phase 2/3 trial of Proellex for endometriosis in 3Q 2012 |
| RVX | 1.36 | Phase 2b | 09/30/2012 | Phase 2b data of RVX-208 (SUSTAIN trial) due 3Q 2012 |
| SNSS | 2.46 | Phase 3 | 09/30/2012 | Phase 3 interim analysis of vosaroxin in combination with cytarabine in first relapsed or refractory AML, in 3Q-2012 |
| SNTS | 5.64 | Phase 3 | 09/30/2012 | Phase 3 Rhucin for Hereditary Angioedema (HAE) attacks to be completed 3Q 2012 |
| ZLCS | 1.01 | Phase 2 | 09/30/2012 | Phase 2b topline data of of Synavive in Rheumatoid Arthritis 3Q 2012 |
| SNTS | 5.64 | PDUFA | 10/16/2012 | PDUFA on or about Oct 16, 2012 for UCERIS™ (budesonide) Tablets 9 mg for the induction of remission of mild to moderate active ulcerative colitis |
| IPXL | 20.97 | PDUFA | 10/21/2012 | PDUFA date October 21, 2012 of IPX066 for the treatment of idiopathic Parkinson’s disease (PD) |
| UTHR | 41.64 | PDUFA | 10/27/2012 | PDUFA October 27, 2012 for treprostinil diethanolamine sustained release tablets for the treatment of pulmonary arterial hypertension |
| CRTX | 5.27 | PDUFA | 10/29/2012 | PDUFA date of October 29, 2012 for CRTX 080, in patients with hyponatremia. |
| ACAD | 1.42 | Phase 3 | 12/31/2012 | Phase 3 completion of Pimavanserin in patients with Parkinson's Disease later in 2012 |
| ACRX | 3.50 | Phase 3 | 12/31/2012 | Phase 3 topline data of ARX-01 for post-operative pain following open abdominal surgery due 2H 2012 (two Phase 3 trials). Third Phase 3 trial data due late 2012/early 2013 |
| AEGR | 14.14 | Phase 3 | 12/31/2012 | Phase 3 initiation of Lomitapide for familial chylomicronemia sometime 2012 |
| AEZS | 0.46 | NDA filing | 12/31/2012 | NDA filing for diagnostic test for Adult Growth Hormone Deficiency (AGHD) likely sometime 2012 |
| AEZS | 0.46 | Phase 3 | 12/31/2012 | Phase 3 initiation of AEZS-108 for endometrial cancer during 2012 |
| ALNY | 9.91 | Phase 2 | 12/31/2012 | Phase 2 initiation of ALN-TTR02 for Transthyretin-mediated amyloidosis (ATTR) during 2H 2012 |
| ALTH | 1.79 | Phase 2 | 12/31/2012 | Phase 2 Bladder Cancer Data expected sometime in 2012 |
| ALTH | 1.79 | Phase 2 | 12/31/2012 | Phase 2 Breast Cancer Data expected sometime in 2012 |
| AMRN | 10.07 | | 12/31/2012 | Initiation of REDUCE-IT cardiovascular outcomes trial by end of 2012 |
| ANAC | 5.59 | Phase 2 | 12/31/2012 | Phase 2 safety / PK and efficacy study of AN2728 in atopic dermatitis in adolescents are due in 2H 2012. |
| ANX | 0.54 | Phase 3 | 12/31/2012 | Phase 3 initiation for Sickle cell disease by end of 2012 |
| ARQL | 5.78 | Phase 3 | 12/31/2012 | Phase 3 MARQUEE trial in patients with non-squamous non-small cell lung cancer (NSCLC) - complete patient enrollment in 2012 with interim data also due later in 2012 |
| ARRY | 3.58 | Phase 2 | 12/31/2012 | Phase 2 Selumetinib (AZD6244) + plus dacarbazine for melanoma due in 2012 |
| ASTX | 1.59 | Phase 2 | 12/31/2012 | Phase 2 data of SGI-110 for AML/MDS due late 2012 |
| BCRX | 3.30 | | 12/31/2012 | Partnership required for Phase 3 initiation of BCX4208 for gout due by end of 2012 |
| CLDX | 4.11 | Phase 2 | 12/31/2012 | Phase 2 initiation of CDX-1135 in dense deposit disease (DDD) during 2H 2012 |
| CLSN | 1.76 | Phase 3 | 12/31/2012 | Phase 3 ThermoDox for liver cancer 380 PFS Events Projected to Occur in Late 2012 |
| CLVS | 18.49 | Phase 3 | 12/31/2012 | Phase 3 topline data of CO-101 for pancreatic cancer due 4Q 2012 |
| CTIC | 0.86 | NDA filing | 12/31/2012 | NDA withdrawn for Pixantrone for NHL. Plans to resubmit during 2012 |
| CTIC | 1.29 | Phase 3 | 12/31/2012 | Initiate Phase 3 Tosedostat for MDS 2H 2012 |
| CTIC | 1.29 | Phase 2 | 12/31/2012 | Phase 2 Data Pixantrone for breast cancer due 2012 |
| CYTK | 1.04 | Phase 2 | 12/31/2012 | Phase 2a CK-2017357 for myasthenia gravis due 2H 2012 |
| DEPO | 5.12 | NDA filing | 12/31/2012 | NDA filing of Serada for hot flashes due to be filed 2H 2012 |
| DRRX | 0.76 | NDA filing | 12/31/2012 | NDA filing of POSIDUR late 2012 dependent on outcome of Pre-NDA meeting |
| DYAX | 1.61 | Phase 2 | 12/31/2012 | Phase 2 data of Ecallantide for ACE Inhibitor-Induced Angioedema due 2H |
| FOLD | 4.67 | Phase 3 | 12/31/2012 | Phase 3 enrolment of Migalastat HCl monotherapy for Fabry Disease due to be completed by end of 2012. |
| GERN | 1.37 | Phase 2 | 12/31/2012 | Phase 2 initiation of GRN1005 for GBM 2012 |
| GERN | 1.37 | Phase 2 | 12/31/2012 | Phase 2 Topline data of Imetelstat for breast cancer due by end of 4Q 2012 |
| GERN | 1.37 | Phase 2 | 12/31/2012 | Phase 2 Topline data of Imetelstat for multiple myeloma due by end of 4Q 2012 |
| GERN | 1.37 | Phase 2 | 12/31/2012 | Phase 2 Topline data of Imetelstat for breast cancer due by end of 4Q 2012 |
| GERN | 1.37 | Phase 2 | 12/31/2012 | Phase 2 Topline data of Imetelstat for essential thrombocythemia due by end of 4Q 2012 |
| GENT | 9.63 | NDA filing | 12/31/2012 | Company "hopeful" of filing new NDA for Defibrotide during 2012. Withdrew original NDA during 2011 |
| HGSI | 13.99 | Phase 3 | 12/31/2012 | Phase 3 initiation of Benlysta for Vasculitis sometime during 2012 |
| HGSI | 13.99 | Phase 3 | 12/31/2012 | Phase 3 initiation of Benlysta for Active lupus nephritis sometime during 2012 |
| HGSI | 13.99 | Phase 2 | 12/31/2012 | Phase 2 enrolment of Mapatumumab with sorafenib for cardiovascular disease sometime during 2012 |
| IDIX | 8.08 | Phase 2b | 12/31/2012 | Phase 2b data of IDX184 for HCV due 2H 2012 |
| IMGN | 13.51 | Phase 2 | 12/31/2012 | Phase 2 Data of IMGN901 lorvotuzumab mertansine for small-cell lung cancer SCLC due 2H 2012 |
| IMMU | 3.40 | Phase 3 | 12/31/2012 | Phase 3 initiation of 90Y-clivatuzumab tetraxetan in patients with advanced pancreatic cancer possibly late 2012 |
| INCY | 21.75 | Phase 2 | 12/31/2012 | Phase 2 initiation of INCB24360 in patients with ovarian cancer late 2012 |
| INCY | 21.75 | Phase 2 | 12/31/2012 | Phase 2 data of LY3009104 in patients with rheumatoid arthritis due late 2012 |
| INFI | 12.45 | Phase 2 | 12/31/2012 | Phase 2 enrolment of Retaspimycin Hydrochloride with docetaxel for NSCLC to be completed 2H 2012 |
| INFI | 12.45 | Phase 2 | 12/31/2012 | Phase 1b/2 Retaspimycin Hydrochloride with docetaxel topline data of dose-escalation portion of the Phase 1b/2 trial for NSCLC due 2H 2012 |
| INFI | 12.45 | Phase 2 | 12/31/2012 | Phase 2 topline data of IPI-926 Saridegib for Pancreatic Cancer due 2H 2012 |
| INFI | 12.45 | Phase 2 | 12/31/2012 | Phase 2 topline data of Saridegib for Myelofibrosis due 2H 2012 |
| INFI | 12.45 | Phase 2 | 12/31/2012 | Phase 2 enrolment of IPI-926 Saridegib for Chondrosarcoma complete 2H 2012 |
| ISTA | 9.07 | Phase 3 | 12/31/2012 | Phase 3 initiation of T-PRED for Uveitis and allergic conjunctivitis during 2H 2012 |
| ITMN | 10.08 | Phase 3 | 12/31/2012 | Phase 3 enrolment due to be completed by end of 2012 for Pirfenidone for Idiopathic pulmonary fibrosis |
| LGND | 14.15 | NDA filing | 12/31/2012 | GSK expects to release safety data for its PROMCATA trial in the treatment of thrombocytopenia in patients with Hepatitis C during 1H 2012 and file a sNDA during 2012 |
| LGND | 12.11 | Phase 3 | 12/31/2012 | Merck will initiate Phase 3 trials for cancer drug dinaciclib - no timeline |
| MNKD | 1.60 | | 12/31/2012 | Expect to complete both trials requested by FDA following CRL for AFREZZA by or near the end of 2012. Expect to submit the results to the FDA as an amendment to NDA during 1H 2013. |
| NBIX | 6.55 | Phase 2 | 12/31/2012 | Phase 2 trial of elagolix in the treatment of uterine fibroids is expected to be completed in late 2012 |
| NBIX | 6.55 | Phase 2b | 12/31/2012 | Data from Phase 2b trial of Phase2b trial of NBI-98854 in tardive dyskinesia patients due by end of 2012 |
| | | | |
| NLNK | 11.21 | Phase 3 | 12/31/2012 | Interim Phase 3 pancreatic cancer data due late 2012 |
| NPSP | 7.13 | NDA filing (BLA) | 12/31/2012 | File BLA NPSP558 for Hypoparathyroidism towards end of 2012 |
| OMER | 9.52 | Phase 3 | 12/31/2012 | Phase 3 OMS103HP for arthroscopy data due 2H 2012 |
| OMER | 9.52 | Phase 3 | 12/31/2012 | Phase 3 second trial data of OMS302 for intra-ocular lens replacement surgery 2H 2012 |
| OPXA | 0.47 | Phase 2b | 12/31/2012 | Phase 2b initiation of Tovaxin for Secondary Progressive MS (SPMS) possibly by end of 2012 subject to funding |
| OGXI | 12.73 | Phase 3 | 12/31/2012 | Initiate second Phase 3 trial of Custirsen for castrate-resistant prostate cancer 2H 2012 |
| OGXI | 12.73 | Phase 3 | 12/31/2012 | Complete enrolment in first Phase 3 trial of Custirsen for castrate-resistant prostate cancer 2H 2012 |
| OGXI | 12.73 | Phase 3 | 12/31/2012 | Phase 3 initiation trial of Custirsen for NSCLC 2H 2012 |
| OGXI | 12.73 | Phase 2 | 12/31/2012 | Iniatiate Phase 2 OGX-427 in castrate-resistant prostate cancer later in 2012 |
| OXGN | 0.88 | Phase 3 | 12/31/2012 | Possible initiation of Phase 3 ZYBRESTAT clinical program in anaplastic thyroid cancer (ATC) in 4Q 2012 |
| PBTH | 4.95 | Phase 3 | 12/31/2012 | Phase 3 initiation of hGH-CTP in adults with growth hormone deficiency during 2012 |
| PPHM | 0.44 | Phase 2 | 12/31/2012 | Phase 2 final overall survival data Bavituximab for first line NSCLC due 2H 2012 |
| QLTI | 6.70 | Phase 2 | 12/31/2012 | Phase 2 data of Punctal Plug Drug Delivery System (PPDS) for the treatment of Glaucoma 2H 2012 |
| RIGL | 7.55 | Phase 2 | 12/31/2012 | Phase 3 interim data of Fostamatinib for rheumatoid arthritis due 2H 2012 |
| RPRX | 7.40 | Phase 2 | 12/31/2012 | Phase 2 data of Proellex in a vaginal administration study for uterine fibroids in 4Q 2012, followed by End of Phase 2 meeting with FDA and possible Phase 3 initiation late 2012 or early 2013 |
| SCMP | 8.00 | Phase 2 | 12/31/2012 | Phase 2 initiation of Unoprostone isopropyl - (rescula) for Dry age-related macular degeneration (dry AMD) by late 2012 |
| SGEN | 20.06 | Phase 3 | 12/31/2012 | Phase 3 initiation of ADCETRIS for front-line advanced stage Hodgkin lymphoma late 2012 / late 2013 |
| SGEN | 20.06 | Phase 3 | 12/31/2012 | Phase 3 initiation of ADCETRIS for front-line mature T-cell lymphomas, including sALCL late 2012 / early 2013 |
| SGYP | 4.32 | Phase 2/3 | 12/31/2012 | Topline Phase 2/3 data of Plecanatide for Chronic idiopathic constipation (CIC) due 4Q 2012 |
| SGYP | 4.32 | Phase 2 | 12/31/2012 | Phase 2 initiation of Plecanatide for IBS-C sometime during 2012 |
| SNTA | 3.80 | Phase 2b / Phase 3 | 12/31/2012 | Phase 2b Final PFS data and preliminary OS data of Ganetespib in NSCLC due 2H 2012 and initiation of the Phase 3 portion expected during 2H 2012. |
| SNTS | 5.64 | Phase 3 | 12/31/2012 | Phase 3 trial of Rifamycin for Travelers’ diarrhea to be completed 2H 2012 |
| SPPI | 11.08 | Phase 3 | 12/31/2012 | Phase 3 data of Belinostat for Peripheral T-Cell Lymphoma due 4Q 2012 |
| SPPI | 11.08 | Phase 2 | 12/31/2012 | Phase 2 top-line Belinostat results of progression free survival and response rate for Carcinoma of Unknown Primary (CUP) due 2H 2012 |
| THLD | 6.11 | Phase 1/2 | 12/31/2012 | Phase 1/2 topline data of TH-302 for multiple myeloma (408 trial) due by end of 2012 |
| THLD | 6.11 | Phase 1/2 | 12/31/2012 | Phase 1/2 topline data of TH-302 for renal cell carcinoma, gastrointestinal stromal tumors or pancreatic neuroendocrine tumors (410 trial) due by end of 2012 |
| THLD | 6.11 | Phase 2b | 12/31/2012 | Phase 2b overall survival data of TH-302 for pancreatic cancer due 2H 2012 |
| TRGT | 4.12 | Phase 2 | 12/31/2012 | Phase 2 data of TC-TC-5214 for Attention deficit/hyperactivity disorder (ADHD) due 2H 2012 |
| TZYM | 3.00 | Phase 2b | 12/31/2012 | Phase 2b data of TZP-102 for Diabetic gastroparesis due by end of 2012 |
| VICL | 2.84 | Phase 3 | 12/31/2012 | Phase 3 initiation of Collategene for Peripheral arterial disease sometime 2012 |
| VICL | 2.84 | Phase 3 | 12/31/2012 | Phase 3 topline data Allovectin-7 for melanoma late 2012 |
| VICL | 3.39 | Phase 3 | 12/31/2012 | Phase 3 initiation of TransVaxT CMV vaccine for HCT patients during 2H 2012 |
| VICL | 3.39 | Phase 2 | 12/31/2012 | Phase 2 initiation of TransVaxT CMV vaccine for solid organ transplant (SOT) patients during 2H 2012 or shortly after |
| VNDA | 4.02 | NDA filing | 06/30/2013 | NDA filing of Tasimelteon for insomnia due to be filed mid 2013. Phase 3 data due end of 2013 |
| VTUS | 10.50 | Phase 3 | 12/31/2012 | Phase 3 US trial of VEN 307 (diltiazem cream) for Anal fissures due to be initiated 2H 2012 |
| XNPT | 5.83 | Phase 3 | 12/31/2012 | Phase 3 topline data of Arbaclofen placarbil for multiple sclerosis (MS) due late 2012 |
| XOMA | 2.37 | Phase 2 | 12/31/2012 | Phase 2 proof of concept data of XOMA 052 Gevokizumab for Moderate to Severe Acne Vulgaris due 2012 |
| XOMA | 2.37 | Phase 2 | 12/31/2012 | Phase 2 initiation of Gevokizumab for Cardiovascular disease during 2012 |
| YMI | 1.97 | Phase 1/2 | 12/31/2012 | Final CYT387data of Phase 1/2 Core trial due by end 2012. Interim data from Phase 1/2 Extension trial due by end of 2012. Interim data from the BID (twice-daily dosing) Phase 2 trial also due by end of 2012. |
| ZIOP | 4.44 | Phase 3 | 12/31/2012 | Phase 3 data of palifosfamide for metastatic soft tissue sarcoma due 2H 2012 |
| ZIOP | 4.44 | Phase 2 | 12/31/2012 | Phase 2 initiation of Interleukin-12 (IL-12) in 2H 2012 |
| ZLCS | 0.77 | Phase 2 | 12/31/2012 | Phase 2 initiation of Z160 in patients with Neuropathic pain 2H 2012 |
| AEGR | 12.50 | PDUFA | 01/05/2013 | PDUFA date on or about January 5, 2012 for lomitapide in patients with Homozygous familial hypercholesterolemia (HoFH) |
| CPRX | 1.07 | Phase 2 | 01/31/2013 | Phase 2b Top-line data trial evaluating CPP-109 for the treatment of cocaine addiction due early 1Q 2013 - Jan 31 2013 estimate only for calendar purposes |
| ANAC | 5.57 | Phase 3 | 01/31/2013 | Phase 3 topline data of first trial of Tavaborole for Onychomycosis due January 2013 |
| AIS | 2.72 | NDA filing | 03/31/2013 | NDA filing of VIBEX for Rheumatoid arthritis (RA) due 1Q 2013 |
| ANAC | 5.31 | Phase 3 | 03/31/2013 | Phase 3 topline data of second trial of Tavaborole for Onychomycosis due 1Q 2013 |
| ARRY | 3.43 | Phase 2 | 03/31/2013 | Phase 2 topline data of ARRY 502 for asthma due 1Q 2013 |
| ARRY | 3.43 | Phase 2 | 03/31/2013 | Phase 2 data of MEK162 (ARRY-162) for melanoma due by 1Q 2013 |
| ARRY | 3.43 | Phase 2 | 03/31/2013 | Phase 2 ARRY-520 plus dexamethasone data for Refractory Multiple Myeloma MM due by early 2013 |
| ARRY | 3.43 | Phase 1b | 03/31/2013 | Phase 1b combination data for ARRY-520 plus Velcade (bortezomib) in patients with triple-refractory MM |
| ASTX | 1.59 | Phase 2 | 03/31/2013 | Phase 2 SGI-110 data due by early 2013 |
| ASTX | 1.59 | Phase 2 | 03/31/2013 | Phase 2 Amuvatinib data due by early 2013 |
| ATHX | 1.36 | Phase 2 | 03/31/2012 | Phase 2 topline data of Multistem for Ulcerative colitis due early 2013 |
| OMER | 9.52 | NDA filing | 03/31/2013 | NDA filing of OMS302 for intra-ocular lens replacement surgery to be filed first part of 2013 |
| OXGN | 0.88 | Phase 2 | 03/31/2013 | Phase 2 progression-free survival data for ovarian cancer due early 2013 |
| POZN | 7.73 | NDA filing | 03/31/2013 | File NDA 1Q 2013 of PA32540 for secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers |
| RVX | 1.50 | Phase 2b | 03/31/2013 | Phase 2b data of RVX-208 (ASSURE trial) due Q1 2013 |
| THLD | 6.15 | Phase 3 | 03/31/2013 | Phase 3 interim data of TH-302 for soft tissue sarcoma due start of 2013 |
| TSPT | 6.99 | Phase 2 | 03/31/2013 | Phase 2 TO-2061 in adult patients with obsessive compulsive disorder (OCD) data due 1Q 2013 |
| TSRX | 4.99 | Phase 3 | 03/31/2013 | Phase 3 data of second trial of torezolid phosphate for ABSSSI due early 2013 |
| ALKS | 16.42 | Phase 3 | 06/30/2013 | Pivotal ALKS 9070 in patients with schizophrenia data due mid 2013 |
| ALKS | 16.42 | Phase 2 | 06/30/2013 | Phase 2 data ALKS 5461 for Depression due 1H 2013 |
| ANAC | 5.59 | Phase 2 | 06/30/2013 | Phase 2 data of AN2728 in atopic dermatitis -safety / PK and efficacy study in children and the Phase 2 dose-ranging bilateral trial are due in 1H 2013. |
| ANAC | 5.31 | NDA Filing | 06/30/2013 | NDA filing of Tavaborole for Onychomycosis due 1H 2013 |
| ANAC | 5.59 | Phase 3 | 06/30/2013 | Phase 3 initiation of AN2728 in atopic dermatitis mid 2013 |
| BDSI | 4.01 | NDA Filing | 06/30/2013 | NDA filing of BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence in 1H 2013 |
| GERN | 1.37 | Phase 2 | 06/30/2013 | Phase 2 GRN1005 data of brain metastases arising from breast cancer due mid 2013 |
| GERN | 1.37 | Phase 2 | 06/30/2013 | Phase 2 GRN1005 data of brain metastases arising from NSCLC due mid 2013 |
| GTXI | 3.41 | Phase 3 | 06/30/2013 | Phase 3 data of Enobosarm (OstarineTM, GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer due 1H 2013 |
| IDRA | 2.08 | Phase 2 | 06/30/2013 | Phase 2 trial IMO-3100 for Psoriasis expected to be completed during 1H 2013 |
| IPXL | 20.97 | Phase 2b | 06/30/2013 | Phase 2b data of IPX159 for restless legs due mid 2013 |
| MDCO | 20.88 | NDA filing | 06/30/2013 | Possible NDA filing of Oritavancin for ABSSSI 1H 2013 |
| MNKD | 1.60 | NDA filing | 06/30/2013 | Expect to complete both trials requested by FDA following CRL for AFREZZA by or near the end of 2012. Expect to submit the results to the FDA as an amendment to NDA during 1H 2013. |
| NBY | 0.99 | Phase 2b | 06/30/2013 | Phase 2b data for Viral conjunctivitis due 1H 2013 |
| VNDA | 4.02 | NDA filing | 06/30/2013 | NDA filing of Tasimelteon for insomnia due to be filed mid 2013. Phase 3 data due end of 2013 |
| VNDA | 4.02 | Phase 2b/3 | 06/30/2013 | Phase 2b/3 data of Tasimelteon for depression due 1H 2013 |
| BIOD | 0.65 | NDA filing | 12/31/2013 | NDA filing of Liquid glucagon formulation for use as a rescue treatment for patients experiencing severe hypoglycemia projected for 4Q 2013 or 1Q 2014 |
| CTIC | 1.29 | Phase 3 | 12/31/2013 | Phase 3 interim analysis of OPAXIO for ovarian cancer due 2013 |
| INCY | 21.75 | Phase 3 | 12/31/2013 | Phase 3 data of INCB18424 ruxolitinib in patients with Polycythemia Vera due 2H 2013 |
| INCY | 21.75 | Phase 2 | 12/31/2013 | Phase 3 data of INCB18424 ruxolitinib in combination with capecitabine in patients with refractory metastatic pancreatic cancer due 2H 2013 |
| INCY | 21.75 | Phase 2b | 12/31/2013 | Phase 2b data of LY3009104 in patients with Psoriasis due 2013 |
| INSM | 2.87 | ARIKACE | 12/31/2013 | Phase 3 European topline data of Arikace in Cystic Fibrosis (CF) patients with Pseudomonas aeruginosa (Pa) lung infections due 2H 2013. |
| PBMD | 4.84 | Phase 3 | 12/31/2013 | Phase 3 trial of CVac as a maintenance treatment for ovarian cancer due to complete enrolment Q3 or Q4 2013 |
| ONTY | 3.43 | Phase 3 | 12/31/2013 | Phase 3 data of Stimuvax for NSCLC due 2013 |
| BNHLF | 0.39 | Phase 3 | 12/31/2013 | Phase 3 data of Urocidin for bladder cancer due end of 2013 |
| RPRX | 7.40 | NDA Filing | 03/31/2014 | Possible NDA filing of Androxal for the treatment of secondary hypogonadism early 2014 |
| ECYT | 4.52 | Phase 2 | 03/31/2014 | Phase 2 PFS data of EC145 for NSCLC due early 2014 |
| ECYT | 4.52 | Phase 2 | 06/30/2014 | Phase 3 PFS data of EC145 for ovarian cancer due 1H 2014 |
| ITMN | 15.28 | Phase 3 | 06/30/2014 | Phase 3 pirfenidone study, ASCEND for IPF, data due 1H 2014. |
| OREX | 3.44 | NDA filing | 06/30/2014 | Possible NDA filing mid-2014 for Contrave for obesity, pending data from cardiovascular outcomes trial |
| HGSI | 13.99 | Phase 3 | 12/31/2014 | Phase 3 data of Subcutaneous BENLYSTA for lupus due 2H 2014 |
